Claims-based diagnostic and procedure codes are valid for identifying certain cardiovascular and gastrointestinal serious adverse events in pharmacoepidemiology research.
Answers are grounded in this paper and cite their sources.
Supports claims-based surveillance for select CV/GI events; leaves open broader validation across outcomes and populations.
The results suggest that, for certain adverse events, claims data can serve as the basis for pharmacoepidemiology research and drug safety surveillance in the US.
No takes yet. Share an insight, caveat, or question.
Wahl et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: